Paclitaxel-resistant advanced recurrent breast cancer: A case of partial response due to addition of bevacizumab to paclitaxel therapy: A case report

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Ishizuna, Kazuo ^a   Ninomiya, Jun ^a,b   Kojima, Makoto ^a   Kawashima, Miho ^a   Nozaki, Miwako ^a   Yamagishi, Hidetsugu ^a   Ueda, Yoshihiko ^a   Oya, Masatoshi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b Ninomiya Hospital   (Japan)

Author keywords

Bevacizumab; Breast cancer; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; MONOCLONAL ANTIBODY; PACLITAXEL;

AGED; BREAST NEOPLASMS; CASE REPORT; DRUG RESISTANCE; FEMALE; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL;

EID: 84879810331     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-254     Document Type: Article

References (10)

1. Angiogenesis inhibitors in the management of breast cancer. Bossung V, Harbeck N, Curr Opin Obstet Gynecol 2010 22 1 79 86 10.1097/GCO.0b013e328334e462 19952746
2. The role of vascular endothelial growth factor in pathological angiogenesis. Ferrara N, Breast Cancer Res Treat 1995 36 2 127 137 10.1007/BF00666035 8534862
3. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Kim KJ, Li B, Winer J, Armanini M, Gillett N, et al. Nature 1993 362 6423 841 844 10.1038/362841a0 7683111
4. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, et al. Nat Med 2004 10 2 145 147 10.1038/nm988 14745444
5. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, et al. Cancer Res 1997 57 20 4593 4599 9377574
6. Bevacizumab improves the delivery and efficacy of paclitaxel. Yanagisawa M, Yorozu K, Kurasawa M, Nakano K, Furugiki K, et al. Anticancer Drugs 2010 21 7 687 694 20559127
7. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, et al. N Engl J Med 2007 357 26 2666 2676 10.1056/NEJMoa072113 18160686
8. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, et al. J Clin Oncol 2010 28 20 3239 3247 10.1200/JCO.2008.21.6457 20498403
9. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, et al. J Clin Oncol 2011 29 10 1252 1260 10.1200/JCO.2010.28.0982 21383283
10. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation. Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestolozzi BC, Fink D, et al. Eur J Cancer 2009 45 8 1397 1406 10.1016/j.ejca.2008.12.016 19147344